Köhrer et al. likewise showed an anti-tumorigenic potential of SYK inhibition by PRT318 in pre-B-ALL cell lines (BCR+), whereas pro-B-ALL cell lines were not affected (BCR−) [4]. This evidence concerns the gene BCR and acute lymphoblastic leukemia.